JP2021512142A5 - - Google Patents

Info

Publication number
JP2021512142A5
JP2021512142A5 JP2020560590A JP2020560590A JP2021512142A5 JP 2021512142 A5 JP2021512142 A5 JP 2021512142A5 JP 2020560590 A JP2020560590 A JP 2020560590A JP 2020560590 A JP2020560590 A JP 2020560590A JP 2021512142 A5 JP2021512142 A5 JP 2021512142A5
Authority
JP
Japan
Prior art keywords
seq
peptide
influenza hemagglutinin
antigen
group
Prior art date
Application number
JP2020560590A
Other languages
English (en)
Japanese (ja)
Other versions
JP7542257B2 (ja
JP2021512142A (ja
JPWO2019145475A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/051853 external-priority patent/WO2019145475A2/en
Publication of JP2021512142A publication Critical patent/JP2021512142A/ja
Publication of JP2021512142A5 publication Critical patent/JP2021512142A5/ja
Publication of JPWO2019145475A5 publication Critical patent/JPWO2019145475A5/ja
Priority to JP2024134738A priority Critical patent/JP2024160341A/ja
Application granted granted Critical
Publication of JP7542257B2 publication Critical patent/JP7542257B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020560590A 2018-01-25 2019-01-25 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法 Active JP7542257B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024134738A JP2024160341A (ja) 2018-01-25 2024-08-13 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18153348 2018-01-25
EP18153348.0 2018-01-25
PCT/EP2019/051853 WO2019145475A2 (en) 2018-01-25 2019-01-25 Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024134738A Division JP2024160341A (ja) 2018-01-25 2024-08-13 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法

Publications (4)

Publication Number Publication Date
JP2021512142A JP2021512142A (ja) 2021-05-13
JP2021512142A5 true JP2021512142A5 (https=) 2022-02-01
JPWO2019145475A5 JPWO2019145475A5 (https=) 2022-02-01
JP7542257B2 JP7542257B2 (ja) 2024-08-30

Family

ID=61192649

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560590A Active JP7542257B2 (ja) 2018-01-25 2019-01-25 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法
JP2024134738A Pending JP2024160341A (ja) 2018-01-25 2024-08-13 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024134738A Pending JP2024160341A (ja) 2018-01-25 2024-08-13 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法

Country Status (6)

Country Link
US (2) US12239736B2 (https=)
EP (1) EP3743101A2 (https=)
JP (2) JP7542257B2 (https=)
CN (1) CN111954541A (https=)
BR (1) BR112020013405A2 (https=)
WO (1) WO2019145475A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201704135QA (en) * 2012-11-19 2017-06-29 Agency Science Tech & Res Method For Eliciting An Immune Response To An Immunogen
CN114502191B (zh) * 2019-08-01 2026-04-03 Acm生物实验室私人有限公司 通过施用具有关联的抗原的聚合物囊泡群和具有关联的佐剂的聚合物囊泡群来引发免疫应答的方法以及包含这两种聚合物囊泡群的组合物
US11642407B2 (en) 2020-02-28 2023-05-09 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
US20230256082A1 (en) * 2020-04-24 2023-08-17 Acm Biolabs Pte Ltd Vaccine against human-pathogenic coronaviruses
JP2024500360A (ja) * 2020-12-11 2024-01-09 エイシーエム バイオラブズ プライベート リミテッド 関連づけられた抗原および関連づけられたアジュバントを有する２つのポリマーソーム集団を投与することによる、Ｔｈ１／Ｔｈ２免疫応答の調整方法
CA3204785A1 (en) * 2021-02-02 2022-08-11 Madhavan Nallani Sole use of polymersome associated adjuvant for stimulating an immune response
WO2022218957A1 (en) * 2021-04-12 2022-10-20 Acm Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
CN113416788B (zh) * 2021-07-14 2022-04-29 兰州大学 一种与湖羊睾丸性状相关的adpgk基因分子标记及其应用
WO2023183287A2 (en) * 2022-03-21 2023-09-28 The University Of North Carolina At Chapel Hill Composite bioactive compositions and applications thereof
WO2024081641A2 (en) * 2022-10-10 2024-04-18 Northwestern University Methods for preparing protein-conjugated nanocarriers
CN117045809B (zh) * 2023-09-27 2025-08-29 国家纳米科学中心 异种哺乳动物细胞来源的囊泡在制备疫苗载体中的应用
CN120860194A (zh) * 2025-07-15 2025-10-31 中国人民解放军总医院第一医学中心 一种流感病毒纳米疫苗及其制备方法与应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US569825A (en) 1896-10-20 John h
US633425A (en) 1899-01-26 1899-09-19 Louis Henry Clyborne Wire-tightener.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
FR2766205B1 (fr) * 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
DE602004025711D1 (de) 2003-08-21 2010-04-08 Lipotek Pty Ltd In vivo targeting von dendritischen zellen
WO2008060557A2 (en) 2006-11-14 2008-05-22 The Trustees Of The University Of Pennsylvania Efficient nuclear delivery of antisense oligonucleotides
US8323696B2 (en) 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
EP2601262A4 (en) * 2010-08-05 2014-01-22 Agency Science Tech & Res VESIGN STRUCTURE WITH SEVERAL CHAMBERS AND METHOD FOR THEIR EDUCATION
CA2866170A1 (en) 2012-03-12 2013-09-19 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions
SG10201704135QA (en) 2012-11-19 2017-06-29 Agency Science Tech & Res Method For Eliciting An Immune Response To An Immunogen
US10017545B2 (en) * 2013-06-03 2018-07-10 University Of Maryland, College Park Compositions and vaccines comprising vesicles and methods of using the same
EP2898894A1 (en) 2014-01-27 2015-07-29 LTS LOHMANN Therapie-Systeme AG Nano-in-micro particles for intradermal delivery
WO2016055611A1 (en) 2014-10-09 2016-04-14 Universität Basel Self-assembled nanostructures and methods of use thereof
US9636397B2 (en) 2015-03-24 2017-05-02 VaxLiant, LLC Adjuvant compositions and related methods
MX2018010586A (es) * 2016-03-02 2019-03-28 Univ Texas Nanovacuna de activacion de "sting" para inmunoterapia.

Similar Documents

Publication Publication Date Title
JP2021512142A5 (https=)
CN108743939B (zh) 共载抗原、mpla与imq的阳离子磷脂-聚合物杂化纳米粒疫苗佐剂及制备方法与应用
Zhu et al. Co-delivery of antigen and dual agonists by programmed mannose-targeted cationic lipid-hybrid polymersomes for enhanced vaccination
Bonifaz et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination
US20220273792A1 (en) A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes
Shahiwala et al. Nanocarriers for systemic and mucosal vaccine delivery
JP6443646B2 (ja) Ｐｅｇ化リン脂質を担体とするポリペプチドワクチンミセル
Joshi et al. Characterizing the antitumor response in mice treated with antigen-loaded polyanhydride microparticles
JPWO2021019102A5 (https=)
Sunoqrot et al. Lipid-and polymer-based nanocarrier platforms for cancer vaccine delivery
JPWO2019145475A5 (https=)
CN116603068B (zh) 一种多肽疫苗递送载体及其制备方法
Li et al. The finely regulating well-defined functional polymeric nanocarriers for anti-tumor immunotherapy
US20230398207A1 (en) Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant
CN105194663A (zh) 聚乙二醇化磷脂为载体的胶束多肽疫苗
Singh et al. Applications of nanotechnology in vaccine delivery
US20040126421A1 (en) Liposomal system and method of using same
AU2022216818A1 (en) Sole use of polymersome associated adjuvant for stimulating an immune response
Savla et al. Nanoparticles in the development of therapeutic cancer vaccines
Brown et al. Nucleic Acids as Adjuvants
CN120189518A (zh) 疫苗载体组合物、纳米疫苗药物组合物、疫苗制剂及其制备方法
이혜선 Development of adjuvants using cytokine and polymeric particles for efficient mucosal immunization
Sahu et al. Nanoparticulate Vaccines: Mechanistic Insight and Recent Advances
Chesson Supramolecular Peptide Nanofiber Vaccines for Eliciting CD8+ T-cell Responses
TW202444409A (zh) 組成物、疫苗及a型流感的治療方法